PEG-MGF

What it is

IGF-1 is the growth factor through which growth hormone exerts a large part of its effect. The corresponding gene can be read in several ways. Depending on which sections are joined together, precursors with different end pieces, the E-domains, are formed. In humans an insert of 49 base pairs, in rodents of 52, produces a variant with a quite distinct end piece: IGF-1Ec in humans, IGF-1Eb in rodents. Because it responds to mechanical stimuli, the group around muscle researcher G. Goldspink named it mechano growth factor.

What is sold as MGF is not this whole factor. It is a synthetic peptide made of the last 24 amino acids of the E-domain. PEG-MGF is this peptide coupled to polyethylene glycol. PEG is a trick from drug development that protects peptides from rapid breakdown and keeps them in the blood longer. With MGF, however, this is marketing logic, not a tested drug design.

What the muscle does itself

The basic observation is solid. In rabbit muscle, both forms of the IGF-1 message rose sharply within 4 days of stretching. In humans, a 2003 study measured the MGF message in the thigh muscle 2.5 hours after heavy strength training: 10 sets of 6 repetitions at 80 percent of maximal strength. In 8 young subjects, MGF rose markedly; in 7 older subjects aged between 70 and 82, it did not. At rest, MGF was about 100-fold lower than the main form IGF-1Ea.

That is a nice finding: muscle seems to have its own signal for loading and repair, and this signal weakens with age. From this arose the idea that the signal could be supplied from outside. But precisely this step has never been tested in humans.

How it is supposed to work

The short MGF peptide is said to act not via the classic IGF-1 receptor but via its own, as yet unknown pathway. In cell culture it increased the division of myoblasts, the precursors of muscle fibers, and at the same time slowed their maturation. The idea: first provide more building material, then let it fuse. Human satellite cells, the stem cells of muscle, divided for longer under the peptide when they came from newborns or young adults, but not from older donors. Outside muscle, the peptide had a protective effect in animals on heart muscle and nerve cells when their blood supply was interrupted.

What users report

In the strength sports scene, PEG-MGF is traded as a regeneration and building peptide after training, often together with other growth factors. Forums claim it acts only locally and has no systemic side effects. A 2026 review explicitly classifies such reports as anecdotal. They show what users expect, but not what happens in the body.

What the studies show

Hameed 2003 — MGF after strength training

Eight young and seven older subjects completed a heavy single-leg knee extension session; 2.5 hours later the muscle was biopsied. The MGF message rose only in the young. The study shows that the body regulates MGF itself. Nothing was administered.

Fornaro 2014 — the replication attempt

Researchers from two pharmaceutical companies wanted to develop MGF as a muscle drug and first rechecked the cell findings. Up to 500 nanograms per milliliter neither increased the division of mouse or human myoblasts, nor slowed maturation, nor acted on primary muscle stem cells, not even in stabilized form. Mature IGF-1 worked in all systems. The authors’ conclusion: the physiological role of MGF is questionable.

Carpenter 2008 — the sheep heart

In sheep, an infarction was induced and the MGF E-domain was administered. After 8 days, heart function was better preserved and 35 percent less heart muscle was damaged than in the controls. The peptide was not PEGylated and was used directly during the infarction.

Brisson 2014 — larger, but weaker

Mice permanently produced the rodent counterpart of the MGF end piece in muscle via a gene vector. The muscles became larger, and this ran via the IGF-1 receptor. Strength, however, decreased. More mass did not mean more performance here.

Where the data stop

There is not a single peer-reviewed study on PEG-MGF as a substance, neither in animals nor in humans. The US drug regulator FDA states that it found no data whatsoever on use in humans, by any route of administration. A 2026 review therefore places PEG-MGF in the lowest evidence level and emphasizes that the PEG chain fundamentally changes distribution and residence time. Findings on the bare peptide therefore cannot simply be transferred.

The foundation is also shakier than the marketing suggests. A naturally occurring MGF peptide has so far not been detected in cells, tissues or body fluids. The central cell findings could not be repeated in an independent test, and in a 2016 laboratory study short MGF peptides did not activate the IGF-1 receptor at any concentration. Activation of human satellite cells worked only with cells from young donors. Studies on muscle building, strength or regeneration in humans are completely lacking; there is no entry in the ClinicalTrials.gov study registry.

Status, approval and legal

PEG-MGF is not an approved medicine in Germany, the EU or the US and has never been clinically developed. It is sold as a research chemical. WADA lists mechano growth factors under S2.3 of the 2026 prohibited list, banned in and out of competition; MGF peptides have been covered since 2005. The German Anti-Doping Act explicitly names mechano growth factor and MGF variants in its annex. Doping laboratories have characterized various MGF variants from illegal sources, including a seized product in 2017. The FDA listed PEG-MGF as a compounding substance with possible significant risks; the nomination was withdrawn, but the assessment remains on the page as of April 22, 2026.

Safety

There are no safety data in humans. As concrete points, the FDA cites a possible significant risk of immune reactions, impurities and the difficult chemical characterization of the peptide. A second point concerns growth: MGF is produced more strongly in prostate cancer tissue and its precursors than in healthy tissue, and the synthetic E-peptide stimulated prostate cancer cells to grow in the laboratory, independently of the IGF-1 receptor. This is a laboratory finding, not proof in humans, but for cancer or a history of cancer there is no data basis for use. Pregnant women, breastfeeding women and adolescents have not been studied either. Then there is the product question: various MGF variants are in circulation, and what is in an ampoule is not known without analysis.

Sources

• Hameed et al., J Physiol 2003 (MGF after resistance exercise, young and old)
• Yang and Goldspink, FEBS Lett 2002 (MGF and myoblasts)
• Matheny et al., Endocrinology 2010 (review, no natural MGF peptide detected)
• Kandalla et al., Mech Ageing Dev 2011 (human satellite cells)
• Fornaro et al., Am J Physiol Endocrinol Metab 2014 (findings not reproducible)
• Carpenter et al., Heart Lung Circ 2008 (myocardial infarction in sheep)
• Brisson et al., Am J Physiol Endocrinol Metab 2014 (mass without strength)
• Armakolas et al., Prostate 2010 (MGF and prostate cancer cells)
• Dominikowski et al., Front Endocrinol 2026 (review, PEG-MGF without human studies)
• FDA, bulk drug substances that may present significant safety risks (PEG-MGF)